Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.
Biomarker and diagnostic research for myelodysplastic/myeloproliferative neoplasm has been reported in the published literature.
96 clinical trials registered, 47 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 41 PHASE2, 37 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05031897](https://clinicaltrials.gov/study/NCT05031897) |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Two Step Haplo With Radiation Conditioning |
PHASE2 |
Thomas Jefferson University |
RECRUITING |
[NCT03964506](https://clinicaltrials.gov/study/NCT03964506) | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | EARLY_PHASE1 | Omar Aljitawi | RECRUITING |
[NCT05788679](https://clinicaltrials.gov/study/NCT05788679) | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | PHASE2 | Karolinska University Hospital | RECRUITING |
[NCT05554406](https://clinicaltrials.gov/study/NCT05554406) | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT03683433](https://clinicaltrials.gov/study/NCT03683433) | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | PHASE2 | M.D. Anderson Cancer Center | RECRUITING |
43 publications have been identified in PubMed for myelodysplastic/myeloproliferative neoplasm. Research spans Case Report / Case Series (30%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 | 30% |
Research summaries | 9 | 21% |
Laboratory research | 9 | 21% |
Testing and diagnosis research | 4 | 9% |
Clinical study results | 3 | 7% |
Disease patterns and progression | 3 | 7% |
Other research | 1 | 2% |
New treatment approaches | 1 | 2% |
Biswas N (2026). [PMID: 42109987](https://pubmed.ncbi.nlm.nih.gov/42109987/). *Cureus*. [Case Report / Case Series]
Sharidah SA (2026). [PMID: 41925074](https://pubmed.ncbi.nlm.nih.gov/41925074/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Abdulgayoom M (2026). [PMID: 41945493](https://pubmed.ncbi.nlm.nih.gov/41945493/). *Acta Haematol*. [Review / Meta-Analysis]
Itonaga H (2026). [PMID: 41937388](https://pubmed.ncbi.nlm.nih.gov/41937388/). *Br J Haematol*. [Epidemiology / Natural History]
Erdogan Yucel E (2026). [PMID: 42195121](https://pubmed.ncbi.nlm.nih.gov/42195121/). *Medicina (Kaunas)*. [Review / Meta-Analysis]
Cha S (2026). [PMID: 41405191](https://pubmed.ncbi.nlm.nih.gov/41405191/). *Veterinary medicine and science*. [Case Report / Case Series]
Eren OC (2026). [PMID: 42257711](https://pubmed.ncbi.nlm.nih.gov/42257711/). *Virchows Arch*. [Diagnostic / Biomarker]
Nahmod KA (2025). [PMID: 39704386](https://pubmed.ncbi.nlm.nih.gov/39704386/). *Leukemia & lymphoma*. [Case Report / Case Series]
Sastow D (2025). [PMID: 40613931](https://pubmed.ncbi.nlm.nih.gov/40613931/). *Current hematologic malignancy reports*. [Review / Meta-Analysis]
Arun B (2025). [PMID: 40336920](https://pubmed.ncbi.nlm.nih.gov/40336920/). *Journal of hematology*. [Review / Meta-Analysis]